Login / Signup

Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression.

Solène-Florence Kammerer-JacquetCamille GandonFrederic DugayBrigitte LaguerreBenoit PeyronnetRomain MathieuGrégory VerhoestKarim BensalahXavier LeroySebastien AubertCatherine VermautFabienne EscandeVirginie VerkarreEva M ComperatDamien AmbrosettiFlorence PedeutourMarc-Antoine Belaud-RotureauNathalie Rioux-Leclercqnull null
Published in: Histopathology (2022)
TFEB-amplified RCC is a rare molecular subgroup with variable morphology whose diagnosis is confirmed by FISH analysis. The complex alterations identified by CGH are consistent with an aggressive clinical behaviour. The coamplification of VEGFA and the expression of PDL1 could suggest a potential benefit from antiangiogenics and targeted immunotherapy in combination for these aggressive tumours.
Keyphrases
  • renal cell carcinoma
  • poor prognosis
  • binding protein
  • randomized controlled trial
  • clinical trial
  • cancer therapy